Regen BioPharma, Inc. (RGBP)
Regen BioPharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in La Mesa, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,155. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -302.5%. Its beta of 0.23 implies it has historically moved less than the broad market.
Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene. This modulation is strategically aimed at activating immune cells for oncology treatments and suppressing them for autoimmune conditions. Its therapeutic pipeline and product development are currently in their initial phases. Established in 2012, the firm operates from its headquarters in La Mesa, California.
Regen BioPharma, Inc. is most often compared with the following Healthcare names: